Figure 6.

Investigation of neomorphic activities of BRD4 and HDAC6 PROTACs as compared to reference compounds. (A) Quantification of Western blot band intensities after treating the respective cell line with compound at the indicated conditions. Heatmap colors refer to the remaining protein levels after cell treatment. Values are normalized to respective loading controls and to DMSO-treated conditions and represent an average of at least two independent experiments. POM: pomalidomide. dBET57: BRD4 PROTAC. A6: HDAC6 PROTAC. (B) Influence on the pomalidomide-sensitive zinc-finger protein IKZF3 in cells by IMiDs, benzamide-type CRBN ligands, and BRD4 degraders. Cells stably expressing IKZF3-GFP were treated with PROTACs followed by flow cytometry to assess IKZF3 degradation. The graph shows the average of normalized GFP/mCherry ratios for drug-treated versus untreated cells (n = 3).